Metabolic activity of neutrophils and monocytes in the peripheral blood at the viral hepatitis C

2015 ◽  
Vol 21 (31) ◽  
pp. 14-18
Author(s):  
Цховребов ◽  
Alan Tskhovrebov ◽  
Плахтий ◽  
Lyudmila Plakhtiy ◽  
Гатиева ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Metabolic Activity ◽  
Peripheral Blood ◽  
Clinical Symptoms ◽  
Clinical Manifestations ◽  
Control Group ◽  
Healthy Individuals ◽  
Viral Hepatitis C ◽  
Severity Of The Disease

Survey of 67 patients with viral hepatitis C was made. Of these comorbidities were identified in 11 patients. The survey was conducted at the height of clinical manifestations, in the waning of clinical symptoms in early convalescence. The control group consisted of 27 healthy individuals. In patients with hepatitis C dysfunction of neutrophils and monocyteswas revealed. These changescorrelate with the severity of the process. A consequence of the metabolic defect is a decrease in phagocytic activity of neutrophils and monocytes, which allows to offer methods of studying the metabolism of peripheral blood phagocytes as additional criteria to assess the severity of the disease, the prognosis of viral Hepatitis C, its outcomes and complications.

scholarly journals SPECIFIC ASPECTS OF CLINICAL COURSE IN CASE OF COMBINATION OF CHRONIC PANCREATITIS AND CONCOMITANT VIRAL HEPATITIS C

2019 ◽  
Vol 72 (4) ◽  
pp. 595-599
Author(s):  
Liliya S. Babinets ◽  
Olena R. Shaihen ◽  
Halyna Ol. Homyn ◽  
Iryna M. Halabitska
Keyword(s):  
Chronic Pancreatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Symptoms ◽  
Clinical Course ◽  
Negative Influence ◽  
Control Group ◽  
Viral Hepatitis C ◽  
Remission Phase

Introduction: In this publication we analyzed the specific aspects of clinical course in case of combination of chronic pancreatitis and concomitant viral hepatitis C. The aim: Discover the clinical course of chronic pancreatitis with concomitant viral hepatitis C . Materials and methods: 57 patients with chronic pancreatitis and concomitant viral hepatitis c were examined. Diagnosis of chronic pancreatitis and viral hepatitis c was verified based on disease history, clinical symptoms and the results of clinical-instrumental tests. Clinical and biochemical investigations in people with chronic pancreatitis were done in exacerbation and unstable remission phases and for people with viral hepatitis C - in stable remission phase. Results: In patients, who have chronic pancreatitis with concomitant hepatitis C, pain, dyspeptic syndromes and defecation disturbances take the major place in clinical course of the disease. These symptoms were more severe than in the control group (possible difference in numbers in the group of patents with isolate viral hepatitis C (p<0,05). Conclusions: According to the studies data-the negative influence of concomitant viral hepatitis C in clinical course of chronic pancreatitis was identified.

scholarly journals Cryoglobulinemic vasculitis as an extrahepatic manifestation of HCV infec- tion

2021 ◽  
Vol 98 (9-10) ◽  
pp. 709-712
Author(s):  
A. E. Geraskin ◽  
L. M. Mosina ◽  
L. V. Chegodaeva
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Antiviral Therapy ◽  
Systemic Disease ◽  
Clinical Manifestations ◽  
Cryoglobulinemic Vasculitis ◽  
Autoimmune Pathology ◽  
Viral Hepatitis C ◽  
Autoimmune Processes

The problem of viral hepatitis C remains highly relevant despite the recent signifi cant advancements in the diagnosis and treatment of this pathology. Chronic hepatitis C is a systemic disease with extrahepatic manifestations. Autoimmune processes leading to cryoglobulinemia can contribute to their development. Basic clinical manifestations include cutaneous vasculitis with palpable purpura, arthralgia-myalgia, neuropathy, and renal complications such as glomerulonephritis. Polyneuropathies develop much earlier than hepatic encephalopathy, which is characteristic of liver damage. A clinical case represented in the article was noted in a patient with a long-term course of viral hepatitis C, manifested with pronounced neurological symptoms and the development of cryoglobulinemic vasculitis. In this case, of all the applied methods of treatment, only adequately conducted antiviral therapy contributed to the stabilization of the clinical manifestations of cryoglobulinemia. The promptness of antiviral therapy is of signifi cant importance, since it is a possibility to prevent the development of severe autoimmune pathology.

scholarly journals Perinatal viral hepatitis C and performance capabilities for its therapy

2014 ◽  
Vol 19 (3) ◽  
pp. 4-8
Author(s):  
L. G Goryacheva ◽  
N. V Rogozina ◽  
V. A Greshnyakova ◽  
V. V Ivanova
Keyword(s):  
Hepatitis C ◽  
Clinical Symptoms ◽  
Antiviral Drug ◽  
Sustained Viral Response ◽  
Hcv Infection ◽  
Control Group ◽  
Viral Hepatitis C ◽  
Significant Difference ◽  
And Performance ◽  
Biochemical Indices

The aim of the study: to establish the rate of the vertical transmission of HCV infection and justify the usefulness of the drug a-IFN2b (Viferon®) in children with perinatal infection with hepatitis C virus (HCV) at the early stages of the disease. There were examined 465 children aged 2.5 months to 3 years old (at the time of the enrollment in the study), born to mothers with HCV infection and the frequency of transmission from mother to child was established to be is 7.1% (33 cases). In 54.5% the genotype 1b was recorded, in 3% - 1a, and in 6.0 % - 2 genotype. Viferon® drug in doses of 3х10 6IU/m 2 was introduced to 17 infants aged from 3 to 12 months (duration of the course: 6 months in cases with 3, 2 genotype and 12 months - in patients with genotype 1). The efficacy of therapy was 58.8 % (RNA HCV (-) 10 cases. In prescription the drug to children under 6 months the efficacy was 62.5%, under 6-12 months - 44.4%. In the control group (16patients) spontaneous viral clearance was established to be in 18.7% of cases. The medication did not cause adverse effects and was well tolerated by children. In none out of the 17 children treated with the drug Viferon®, we have not reported adverse events (clinical symptoms, abnormalities in the hemogram and biochemical indices). The obtained data confirm the expediency of the early use of antiviral drug Viferon® in the treatment of children with perinatal HCV. Nо significant difference in the efficacy of therapy in different genotypes of the virus was identified. Virtually in all children (9 out of 10 children) responded to Viferon® therapy, there was noted Sustained Viral Response

MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C

2020 ◽  
pp. 72-75
Author(s):  
O. P. Shevchenko-Makarenko ◽  
L. R. Shostakovych-Koretska ◽  
V. E. Dosenko ◽  
T. I. Drevytska
Keyword(s):  
Gene Expression ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Biological Marker ◽  
Chronic Viral Hepatitis ◽  
Expression Level ◽  
Healthy Individuals ◽  
Hcv Genotype ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis. Key words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.

scholarly journals Significance of genotyping in the diagnosis of arthritis associated with C-viral hepatitis

2021 ◽  
pp. 146-151
Author(s):  
F. N. Shukurova ◽  
D. A. Parpiboeva ◽  
M. Sh. Karimov
Keyword(s):  
Hepatitis C ◽  
Viral Hepatitis ◽  
Clinical Manifestations ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Rheumatic Manifestations ◽  
The Republic ◽  
Relationship Of ◽  
The Relationship ◽  
Subtype 1B

To date, a number of studies have been conducted on the relationship of HCV genotypes with complications such as liver cirrhosis, hepatocellular carcinoma, but research on the correlation of the genotype with extrahepatic clinical manifestations associated with HCV, especially rheumatic manifestations, is insufficient. The purpose of the study is to analyze the most common genotypes of viral hepatitis C in the Republic of Uzbekistan and study their correlation with rheumatic manifestations of HCV. Methods: This study involved 88 patients with HCV infection who received inpatient and subsequent ambulatornoe treatment in Scientific Research Institute of Epidemiology, Microbiology and Infectious diseases of the Republic of Uzbekistan. Diagnostics procedures at the initial level included a set of studies, i. e. clinical, rheumatological and laboratory studies, ultrasound of the joint. In addition, 88 samples of RNA - positive serum from patients diagnosed with HCV were genotyped. Results: the Results showed that genotype 1 of HCV (subtype 1b) is the main genetic variant of HCV in Uzbekistan. Based on the results obtained, the genotypic features of viruses can be markers of the development of extrahepatic clinical manifestations. There is a reliable direct correlation between the incidence and severity of associated arthritis in patients with chronic viral hepatitis C with genotype 1b of the virus according to our research. Conclusions: The results of the study can be provided to help the doctor of the polyclinic service as recommendations that patients with the 1b genotype of the virus have a greater adherence to associated arthritis, and in this case, timely targeted consultation of a specialist is necessary.

scholarly journals Method of DNA-comet assay in the diagnosis of liver fibrosis in patients with chronic viral hepatitis C

2015 ◽  
Vol 20 (2) ◽  
pp. 29-33
Author(s):  
A. F Popov ◽  
A. O Mikhailov ◽  
N. S Ivanova ◽  
A. I Simakova
Keyword(s):  
Hepatitis C ◽  
Liver Fibrosis ◽  
Comet Assay ◽  
Viral Hepatitis ◽  
Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Chronic Viral Hepatitis ◽  
Dna Comet Assay ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

In the study there were included 100 patients, which were selected in 5 group in dependence on the degree of liver fibrosis: I - F0, II - F1, III - F2, IV- F3, V - F4. Sixth (control) group was consisted of 43 healthy volunteers. The performed research has shown the relationship between the stage of fibrosis and the degree of DNA degradation in peripheral blood lymphocytes. The biggest level of DNA destruction in peripheral blood lymphocytes was established in group V patients with chronic viral hepatitis C. This allowed to consider method of DNA-comet assay as promising auxiliary method in the assessment of the formation of liver fibrosis.

scholarly journals Modern clinical laboratory aspects of chronic hepatitis C

2021 ◽  
pp. 37-42
Author(s):  
O. N. Sumlivaia ◽  
M. S. Nevzorova ◽  
A. T. Sayfitova ◽  
S. A. Vysotin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Chronic Hepatitis C ◽  
Clinical Examination ◽  
Liver Damage ◽  
Clinical Laboratory ◽  
Diagnostic Value ◽  
Control Group ◽  
Viral Hepatitis C

Aim. Assess the current diagnostic value of clinical laboratory markers of liver damage in chronic viral hepatitis C. Materials and methods. Comprehensive clinical examination of 194 patients with the diagnosis chronic hepatitis C and 73 almost healthy faces was conducted. Results. According to the clinical examination, 91% of patients have hepatomegaly. According to the results of elastography, the subgroup without fibrosis F0 49 (25%) people, with fibrosis of stages F1-F3-145 (75%) patients. The occurrence of HCV genotypes was: HCV-1-33%, HCV-2-12% and HCV-3-55%. The virusemia indicator showed large variations of values. During the research it was established that indirect indicators of a fibrosis of a liver: levels of AST and ALT, GGTP, a direct and general bilirubin, the APRI index are authentically exceeded by indexes of control group while the level of thrombocytes and de Ritis’s coefficient authentically decrease. Conclusions. The current course of chronic hepatitis C occurs with hepatomegalia, often associated with gastrointestinal and cardiovascular damage. The most common virus among patients is the HVC-3 genotype virus. When examining indirect markers of fibrosis in viral hepatitis C, the APRI test is an early predictor and has high predictive value. Platelet levels decrease with viral liver damage. As a consequence, the APRI index increases and the de Ritis ratio decreases.

scholarly journals Analysis of medical and social factors affecting the formation and course of co-infection HIV, tuberculosis and viral hepatitis

2020 ◽  
Vol 9 (5-6) ◽  
pp. 787-799
Author(s):  
O. V. Azovtseva ◽  
A. M. Panteleev ◽  
А. V. Кarpov ◽  
G. S. Arkhipov ◽  
V. R. Veber ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hiv Infection ◽  
Viral Hepatitis ◽  
Social Factors ◽  
Combined Treatment ◽  
Clinical Manifestations ◽  
Antiretroviral Drugs ◽  
High Rate ◽  
Concomitant Disease ◽  
Viral Hepatitis C

Currently, HIV infection is characterized by emergence of its severe and comorbid forms. Mid-1990 HIV epidemics was expanded due to injection drug users who brought viral hepatitis C to the cohort. Along with developing immunosuppression, opportunistic and AIDS-defining diseases, including tuberculosis emerged. Various combinations of coinfections (HIV infection+tuberculosis±viral hepatitis) affect clinical manifestations and clinical score, reduce the therapeutic efficacy and worsen disease prognosis.Objective: to study an impact medical and social factors on course of TB-co-infection associated with immunosuppression related to HIV infection and viral hepatitis.Materials and methods. Comorbid cases (HIV infection, tuberculosis and chronic hepatitis) dominated by verified TB-infection (n = 137) were analyzed.Results. It was shown that socially maladapted young people with previous experience of intravenous drug and alcohol abuse dominated among subjects with co-infections, half of which were held in penal institutions. More-over, the mean CD4 lymphocyte level in generalized tuberculosis was significantly lower than in patients with significantly reaching 164±21.5 cells. In addition, lung-specific lesions were observed in 73.4% of patients with generalized tuberculosis that developed by initial targeting of the lymphoid system followed by affecting other organs, mainly the central nervous system, urinary system and abdominal organs. Introduction of antiretroviral drugs to anti-TB therapy reduced mortality rate by 8 times. Viral hepatitis was the most common concomitant disease found in co-infected patients, with dominating viral hepatitis C both as a mono-infection (86.8%) as well as in combination with viral hepatitis B (9.43%). In addition, co-morbid viral hepatitis resulted in progression of TB infection affected due to intra-thoracic lymph nodes being involved in tuberculosis process as well as development of opportunistic diseases due to a markedly decreased CD4 cell count. Analysis of potentially aggravating risk factors for developing hepatotoxicity (viral hepatitis, combined treatment with anti-TB and anti-retroviral drugs) did not reveal their any additional negative impact on hepatic functions. Thus, use of a combination therapy with anti-TB and anti-retroviral drugs in co-infected patients was shown to be safe and not accompanied by a high rate of hepatotoxic reactions.

Sign in / Sign up

Export Citation Format

Share Document